No Data
No Data
GSK Is Maintained at Buy by Jefferies
GSK Is Maintained at Buy by Jefferies
Jefferies Maintains Buy on GSK, Raises Price Target to $53
Jefferies analyst Peter Welford maintains GSK (NYSE:GSK) with a Buy and raises the price target from $52.5 to $53.
GSK Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/02/2024 39.51% Jefferies $52.5 → $53 Maintains Buy 05/30/2024 23.72% Goldman Sachs → $47 Initiates Cove
Eli Lilly, Novo Under Pressure as Biden Urges Lower Drug Prices
Heartburn Drug Zantac Litigation: GSK And Other Pharma Giants Face Trial Over Cancer Claims
A Delaware judge has dismissed a request from GSK Plc (NYSE:GSK) and other pharmaceutical companies to appeal a ruling that allows over 70,000 lawsuits alleging the heartburn drug Zantac causes cancer
Moderna Gets $176 Million From the U.S. to Make a Bird Flu Vaccine -- Barrons.com
By Josh Nathan-Kazis The drugmaker Moderna said Tuesday that it had received $176 million from the U.S. government to develop a messenger-RNA based bird flu vaccine for humans. The award, made throu
No Data
Jason Brownz : sell all going to 30